Sun Pharmaceutical Industries has announced the appointment of Kirti Ganorkar as the Managing Director (MD) to succeed Dilip Shanghvi, effective September 1, 2025, with the entire business and all functions reporting to him. This appointment is subject to approval of the shareholders at the upcoming Annual General Meeting.
Ganorkar has been heading India Business at Sun Pharma since June 2019. Under his leadership, the company’s India Business has grown consistently, further increasing its market share. Previously, he has held various leadership roles across business development, marketing, M&A, new product introduction, project management, IP and litigation at Sun Pharma.
He played a key role in driving Sun Pharma’s foray into specialty by securing rights for innovative products such as Ilumya. Ganorkar led Sun Pharma’s entry into Japan and laid initial groundwork for the company’s entry into Europe. He supported the US business with stewardship of several notable generic projects from concept to commercialisation. A chemical engineer and MBA, Ganorkar joined Sun Pharma in 1996.
As Executive Chairman, Shanghvi will continue to chair the Board. He will focus on strengthening Sun Pharma’s specialty portfolio and provide insights towards shaping company’s long-term strategy.
